Quantcast
Last updated on April 17, 2014 at 11:32 EDT

Latest Daiichi Sankyo Stories

2011-10-21 10:45:00

PARSIPPANY, N.J., Oct. 21, 2011 /PRNewswire/ -- Approximately 100 cherry tree saplings were planted in Central Park of Morris County today, the newest park in the Morris County Park System, located in Parsippany Troy-Hills. The planting will create Cherry Lane and celebrate the 100th anniversary of the historic gift of Japanese flowering cherry trees from Tokyo to Washington D.C. in 1912. More than 75 Daiichi Sankyo employee volunteers partnered with the Park Commission staff to plant...

2011-09-08 09:00:00

PARSIPPANY, N.J., Sept. 8, 2011 /PRNewswire/ -- Some of the most enjoyable family moments are spent over a meal. Whether it's a celebration, or a typical weeknight dinner, your favorite family recipe can bring loved ones together. However, if you happen to be one of the more than 12 million diagnosed with type 2 diabetes and high LDL-C or "bad" cholesterol,(1,2) you may either feel guilty indulging in your family's favorites, or deprived that you have to give up the foods you love sharing...

2011-08-17 08:59:00

PARSIPPANY, N.J., Aug. 17, 2011 /PRNewswire/ -- With the US Food and Drug Administration (FDA) approval today of Zelboraf(TM) (vemurafenib), a first-in-class personalized treatment for patients with unresectable (inoperable) or metastatic melanoma with a BRAF V600E mutation as detected by an FDA-approved test, Daiichi Sankyo prepares to enter the US cancer market with its first oral, targeted anti-cancer therapy. "The Zelboraf approval is not only a significant milestone for these...

2011-08-17 07:30:00

PARSIPPANY, N.J., Aug. 17, 2011 /PRNewswire/ -- Daiichi Sankyo, Inc. announced that Mahmoud Ghazzi, MD, PhD has joined Daiichi Sankyo Pharma Development (DSPD) as its new executive vice president of drug development for the Americas region. DSPD, headquartered in Edison, NJ, is responsible for the regional delivery of global clinical trials throughout North, South and Central America. Dr. Ghazzi will work closely with the global development regional heads in Asia, Japan and Europe to...

2011-07-26 00:00:00

BARCELONA, Spain and GERRARDS CROSS, England, July 26, 2011 /PRNewswire/ -- Veeva Systems announced today that Daiichi Sankyo, one of the world's top 20 pharmaceutical companies, is replacing its legacy, on-premise Customer Relationship Management (CRM) system with Veeva CRM in the UK. Daiichi Sankyo will deploy Veeva CRM to all of its commercial teams in the UK including integrated healthcare, specialty care, medical liaison scientists, and head-office teams (i.e., marketing...

2011-07-25 11:36:00

PARSIPPANY, N.J., July 25, 2011 /PRNewswire/ -- Daiichi Sankyo, Inc., announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Welchol® (colesevelam HCl) for Oral Suspension to be mixed with fruit juice or diet soft drinks, offering a new option for adult patients with primary hyperlipidemia and type 2 diabetes. Welchol for Oral Suspension was first approved in 2009 to be mixed with water. Welchol is...

2011-07-19 07:00:00

TOKYO, July 19, 2011 /PRNewswire/ -- Building on its cardiovascular portfolio, Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo), is proud to announce the launch of LIXIANA® (JAN: Edoxaban Tosilate Hydrate, INN: edoxaban) in Japan. This announcement follows the first marketing approval for edoxaban 15 mg and 30 mg tablets by the Japanese Ministry of Health, Labor and Welfare in April 2011 (1), and marks the first time edoxaban is commercially available to...

2011-06-28 09:04:00

PARSIPPANY, N.J., June 28, 2011 /PRNewswire/ -- Daiichi Sankyo, Inc. (DSI) announced today that Danesha Dixon Smith has joined the company as its Vice President of Human Resources. "Hiring and developing results-driven employees who are passionate about their work and committed to patients -- our ultimate customers -- is a priority for our organization," said John P. Gargiulo, President and Chief Executive Officer of Daiichi Sankyo, Inc. "We believe every employee has a direct impact on...

2011-06-14 12:41:00

LISBON, Portugal, June 14, 2011 /PRNewswire/ -- Hovione announced today the international filing of its latest patent covering a new, highly efficient dry powder inhaler (DPI), XCaps. XCaps fills a void in the pulmonary inhalation market, as a device which combines high efficiency in powder dispersion with ease of use. Lung fractions in excess of 70% have been achieved, from a device which only requires two steps to inhalation and which only has two components plus a dust...

2011-05-23 07:00:00

PARSIPPANY, N.J., May 23, 2011 /PRNewswire/ -- Data evaluating the long-term efficacy and safety of olmesartan medoxomil, amlodipine besylate, plus hydrochlorothiazide (OM/AML + HCTZ) in patients with hypertension aged <65 years and greater than or equal to 65 years, showed that the triple therapy at Week 52 was both well-tolerated and effective in maintaining the blood pressure reductions seen in the pivotal study regardless of age.(1) The pre-specified subgroup analysis results,...